{"id":75489,"title":"Braveheart Inv Group (BRH.L) Further update re Paraytec Limited","publisher":"Share Talk","author":"sharetalk","published":"2020-10-16T08:04:00+00:00","modified":"2020-10-16T08:04:00+00:00","canonical_url":"https://www.share-talk.com/braveheart-inv-group-brh-l-further-update-re-paraytec-limited-2/","markdown_url":"https://www.share-talk.com/braveheart-inv-group-brh-l-further-update-re-paraytec-limited-2.md","json_url":"https://www.share-talk.com/braveheart-inv-group-brh-l-further-update-re-paraytec-limited-2.json","category":"Healthcare","categories":["Healthcare"],"tags":["AI","ARTIFICIAL INTELLIGENCE","Braveheart Inv Group","BRH","COVID-19","drugs. Phasefocus","Francis Crick Institute","Hull","imaging","laboratories","Manchester","microscopy","online","Research","science","TECHNOLOGY","Universities","University of Sheffield","virtual demonstrations","York"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1","format":"news","language":"en-GB","content":"**Braveheart Investment Group (AIM: BRH),** is pleased to provide an update concerning progress with proof of concept for a COVID-19 test that Paraytec Limited is conducting with the University of Sheffield.\n\nAs announced on 5 October 2020, proof of concept was achieved for the Optical Detection System. Since then the focus of the Proof of Concept trials have has been on the Capture & Signal Generation Modules.\n\nBraveheart is now pleased to confirm that Proof of Concept has now been achieved for the Capture & Signal Generation Modules, which successfully completes the Proof of Concept trials. The directors of Braveheart believe that this test will be the first to combine a rapid result with very high detection sensitivity. Work will now turn toward the acquisition of clinically relevant data, to facilitate optimisation of the functional capabilities of the test, together with a programme of product refinement and development. Meanwhile, regulatory approval for live virus trials and the acquisition of clinical data is being sought.\n\n**Trevor Brown, CEO Braveheart Investment Group, commented “**This is a phenomenal achievement for all concerned. The inspirational leadership and innovative brilliance of Professor Carl Smythe and his talented team have resulted in proof of concept in a little over four months”\n\nThe information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain."}